---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-013841"
form_type: "8-K"
ticker: "LNTH"
cik: "0001521036"
company_name: "Lantheus Holdings, Inc."
filed_at: "2025-01-28T23:59:59+00:00"
generated_at: "2026-05-27T08:18:52.614765+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Lantheus to acquire Evergreen Theragnostics for $250M upfront plus up to $752.5M in milestones

## Summary
- Upfront cash consideration $250M; potential milestone payments up to $752.5M based on OCTEVY and pipeline products.
- Evergreen adds radiopharmaceutical CDMO manufacturing infrastructure and registrational-stage NET diagnostic OCTEVY.
- Transaction expected to close in second half of 2025, subject to regulatory clearances and customary conditions.
- Lantheus reaffirms FY2024 revenue guidance of $1.51B-$1.52B and adjusted EPS of $6.65-$6.70.

## SEC filing metadata
- accession: 0001193125-25-013841
- form_type: 8-K
- ticker: LNTH
- cik: 0001521036
- company_name: Lantheus Holdings, Inc.
- filed_at: 2025-01-28T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1521036/000119312525013841/0001193125-25-013841-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1521036/000119312525013841/d925405d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-013841
- JSON: https://secwatch.observer/filing/0001193125-25-013841.json
- Plain text: https://secwatch.observer/filing/0001193125-25-013841.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.